Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
Pignata S, Califano D, Lorusso D, Arenare L, Bartoletti M, De Giorgi U, Andreetta C, Pisano C, Scambia G, Lombardi D, Farolfi A, Cinieri S, Passarelli A, Salutari V, De Angelis C, Mignogna C, Priolo D, Capoluongo ED, Tamberi S, Scaglione GL, Arcangeli V, De Cecio R, Scognamiglio G, Greco F, Spina A, Turinetto M, Russo D, Carbone V, Casartelli C, Schettino C, Perrone F. Pignata S, et al. Among authors: carbone v. Ann Oncol. 2024 May 3:S0923-7534(24)00128-5. doi: 10.1016/j.annonc.2024.04.007. Online ahead of print. Ann Oncol. 2024. PMID: 38704093
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
Passarelli A, Carbone V, Pignata S, Mazzeo R, Lorusso D, Scambia G, Canova S, Di Palma T, Tasca G, Mantiero M, Naglieri E, Andreetta C, Rauso M, Brunetti AE, Laera L, Abeni C, Scandurra G, Gambaro AR, Pastore A, Bengala C, Gunnellini M, Farolfi A, Spinello M, Bartoletti M. Passarelli A, et al. Among authors: carbone v. Gynecol Oncol. 2024 Mar 21;183:61-67. doi: 10.1016/j.ygyno.2024.02.029. Online ahead of print. Gynecol Oncol. 2024. PMID: 38518529 Free article.
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
Musacchio L, Salutari V, Pignata S, Braicu E, Cibula D, Colombo N, Frenel JS, Zagouri F, Carbone V, Ghizzoni V, Giolitto S, Giudice E, Perri MT, Ricci C, Scambia G, Lorusso D. Musacchio L, et al. Among authors: carbone v. Int J Gynecol Cancer. 2021 Oct;31(10):1369-1373. doi: 10.1136/ijgc-2021-002593. Int J Gynecol Cancer. 2021. PMID: 34607820 Clinical Trial.
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.
Lorusso D, Ceni V, Muratore M, Salutari V, Nero C, Pietragalla A, Ciccarone F, Carbone V, Daniele G, Scambia G. Lorusso D, et al. Among authors: carbone v. Expert Opin Emerg Drugs. 2020 Dec;25(4):445-453. doi: 10.1080/14728214.2020.1836155. Epub 2020 Oct 20. Expert Opin Emerg Drugs. 2020. PMID: 33040627 Review.
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
Tuninetti V, Virano E, Salutari V, Ricotti A, Pisano C, Ducceschi M, Turitto G, Scandurra G, Petrella MC, Forestieri V, Rizzetto M, Mammoliti S, Artioli G, Cioffi R, Borsotti L, Bellero M, Rognone C, Carbone V, Ferrandina G, Mantiero M, Azzolina C, Geninatti E, Pignata S, Valabrega G. Tuninetti V, et al. Among authors: carbone v. Eur J Cancer. 2024 May;203:114039. doi: 10.1016/j.ejca.2024.114039. Epub 2024 Mar 30. Eur J Cancer. 2024. PMID: 38598922
Survival associated with the use of one-step nucleic acid amplification (OSNA) to detect sentinel lymph node metastasis in cervical cancer.
Bizzarri N, Fedele C, Teodorico E, Certelli C, Pedone Anchora L, Carbone V, Giannarelli D, Fagotti A, Zannoni GF, Valente M, Querleu D, Ferrandina G, Scambia G, Fanfani F. Bizzarri N, et al. Among authors: carbone v. Eur J Surg Oncol. 2024 Apr;50(4):108250. doi: 10.1016/j.ejso.2024.108250. Epub 2024 Mar 5. Eur J Surg Oncol. 2024. PMID: 38461568 Free article.
Protective Role of Conization Before Radical Hysterectomy in Early-Stage Cervical Cancer: A Propensity-Score Matching Study.
Bizzarri N, Pedone Anchora L, Kucukmetin A, Ratnavelu N, Korompelis P, Carbone V, Fedele C, Bruno M, Vizzielli G, Gallotta V, De Vincenzo R, Chiantera V, Fagotti A, Fanfani F, Ferrandina G, Scambia G. Bizzarri N, et al. Among authors: carbone v. Ann Surg Oncol. 2021 Jul;28(7):3585-3594. doi: 10.1245/s10434-021-09695-4. Epub 2021 Feb 23. Ann Surg Oncol. 2021. PMID: 33620615
Investigating the possible impact of peritoneal tumor exposure amongst women with early stage cervical cancer treated with minimally invasive approach.
Pedone Anchora L, Bizzarri N, Kucukmetin A, Turco LC, Gallotta V, Carbone V, Rundle S, Ratnavelu N, Cosentino F, Chiantera V, Fagotti A, Fedele C, Gomes N, Ferrandina G, Scambia G. Pedone Anchora L, et al. Among authors: carbone v. Eur J Surg Oncol. 2021 May;47(5):1090-1097. doi: 10.1016/j.ejso.2020.09.038. Epub 2020 Oct 3. Eur J Surg Oncol. 2021. PMID: 33039294
256 results